Ron Laufer, M.D. Senior Managing Director
Ron started his career as a physician and epidemiologist, before moving into venture capital. In 2001, he co-founded Lilly Ventures, the venture capital arm of Eli Lilly & Company. Later he served as a managing director at Visium Asset Management, a healthcare-focused investment firm, before joining MedImmune Ventures in 2010. He is currently or has been a board member of Adheron Therapeutics (acquired by Roche), Armaron Biosciences, Catabasis Pharmaceuticals (NASDAQ: CATB), G1 Therapeutics and VentiRx.
Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School.